These three are not really the same product. Noom and WeightWatchers are behavior-change subscriptions built on food tracking and coaching. GLP-1 programs are medical services that connect you to a clinician who can prescribe a drug. So the first decision is not which app wins, it is whether the goal is habit change alone or medical treatment of obesity. That answer decides everything downstream, including cost.
What is each one actually treating?
Noom leans on psychology, framing food choices through cognitive prompts and daily lessons. WeightWatchers uses its points system to steer eating patterns, with group support baked into its history. Both aim at the same lever: getting a person to change what and how much they eat, sustained over time. That is worthwhile work, and for many people it is enough.
A GLP-1 program treats obesity as a physiological condition rather than a willpower problem. The 2025 clinical practice guideline update on pharmacotherapy for obesity places medication within a medical model, and recent work on defining clinical obesity reflects the same shift toward treating it as a disease with measurable criteria, not a lifestyle score. That distinction matters because it changes who a given approach is right for.
What does the evidence say about each?
Behavioral programs produce modest average weight loss, typically in the low single-digit percentage range, and most of the benefit depends on staying engaged past the point where motivation fades. That is the honest read across the general body of research on structured diet coaching, and it is worth saying plainly: many people who read Noom reviews expecting transformation are comparing it against results that mostly come from drugs.
The GLP-1 class works differently. These drugs act on appetite and gut signaling, described in detail in the literature on GLP-1 and dual GIP/GLP-1 receptor agonists. The dual agonist tirzepatide traces back to the discovery work on LY3298176, and the AGA clinical practice guideline on pharmacological interventions for adults with obesity supports medication for appropriate candidates. Average weight loss in trials of these agents runs well above what behavioral programs alone achieve, though at the cost of side effects and a monthly bill.
How do the three compare on structure?
| Program type | What it does | Main limitation |
|---|---|---|
| Noom | Psychology-based coaching and food logging | Modest average results; depends on engagement |
| WeightWatchers | Points system, coaching, group support | Same behavioral ceiling; medication is a separate track |
| GLP-1 program (brand) | Clinician-prescribed FDA-approved medication | Cost, side effects, coverage barriers |
| GLP-1 program (compounded) | Compounding-pharmacy medication via telehealth | Not an FDA-approved product |
Where does the oral GLP-1 fit in?
Most GLP-1 treatment has meant weekly injections, which narrows appeal. That is changing. Orforglipron, an oral small-molecule GLP-1 receptor agonist, moved through trials described in the early daily oral GLP-1 study and the larger phase 3 obesity results. It reached the market as documented in the Orforglipron: First Approval record, sold under the brand FOUNDAYO after FDA approval in 2026 for weight management. A pill lowers a real barrier for people who will not inject. It is not investigational, and it should not be described that way.
What about cost, and where do compounded options sit?
App subscriptions run in the low tens of dollars a month. Brand GLP-1 medication lists far higher, and even with manufacturer self-pay programs the sustainable monthly figure sits well above any coaching app. Both Noom and WeightWatchers now sell medication tracks separate from their base plans, so the advertised app price is not the medication price. That gap catches people off guard constantly.
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products and have not been through the process that generated the trial evidence. What they offer is a predictable cash price without insurance in the loop. Supervised telehealth practices such as Noom Med and others including Ro, Hims and Hers, Henry Meds, and LillyDirect publish flat pricing for this reason, with a licensed clinician handling the prescription. The trade is regulatory assurance for cost predictability, and it belongs with a prescriber who knows the case.
Who should skip the medication route?
Plenty of people. If the aim is building steadier eating habits and the numbers do not meet clinical criteria for obesity treatment, a coaching app is the more sensible and far cheaper starting point. Medication is not a shortcut you bolt onto a mild goal. The 2025 pharmacotherapy guideline frames these drugs for defined clinical need, not general slimming, and for people managing related conditions such as metabolic dysfunction-associated steatotic liver disease, the EASL-EASD-EASO guidelines tie treatment to specific medical findings rather than a wish to lose a few pounds.
My blunt take: if someone has never tried structured habit change, spending on a GLP-1 first can be premature. If someone has cycled through diet apps for years with a clinical obesity diagnosis, a coaching subscription alone is often the underpowered choice, and reading another round of Noom reviews will not change that.
Key takeaways
- Noom and WeightWatchers are behavioral programs; GLP-1 programs are medical treatment. Pick the category first.
- Behavioral apps produce modest average results and depend heavily on staying engaged.
- GLP-1 medication shows larger trial results but adds cost, side effects, and coverage hurdles.
- Compounded GLP-1 is not FDA-approved; its appeal is predictable cash pricing, not equivalence to the brand.
See also: Best Peptides Overall 2026: Scored and Ranked
Frequently asked questions
Is Noom or WeightWatchers better for weight loss?
Neither is reliably better on average. Both are behavior-change programs built on tracking, coaching, and habit work, and both produce modest results for people who stay engaged. The bigger split is between either app and a medication-based GLP-1 program, which works through a different mechanism entirely.
Do Noom and WeightWatchers prescribe GLP-1 medication?
Both now offer separate medication tracks that connect users to clinicians who can prescribe GLP-1 drugs. These are add-on services with their own fees, distinct from the base coaching subscription, so the price you see advertised for the app is not the price of the medication route.
Are GLP-1 programs more effective than diet apps?
For people who qualify medically, GLP-1 medication produces larger average weight loss in trials than behavioral programs alone. But the medication carries side effects, cost, and questions about continuing it long term, so effectiveness is only one part of the decision.
Is compounded GLP-1 the same as the brand version?
No. Compounded semaglutide or tirzepatide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule but has not gone through the approval process behind the published trial evidence.
What should someone decide first?
Whether the goal is habit change alone or medical treatment of obesity. That answer decides whether an app subscription or a clinician-led GLP-1 program is the right category, and comparing prices only makes sense inside one category.
